Evidence map›Paper›PMID 35591828›Full record

ArticleArchives of medical science : AMS2022

Chemokine expression in patients with ovarian cancer or benign ovarian tumors.

Marek Nowak, Łukasz Janas, Malwina Soja, Ewa Głowacka, Krzysztof Szyłło, Marcin Misiek, Magdalena Klink

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marek NowakDepartment of Operative Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Łukasz JanasDepartment of Operative Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Malwina SojaDepartment of Operative Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Ewa GłowackaLaboratory Diagnostics Centre, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Krzysztof SzyłłoDepartment of Operative Gynecology and Gynecologic Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Marcin MisiekDepartment of Gynecology, Holy Cross Cancer Centre, Kielce, Poland.
Magdalena KlinkInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Polish Mother’s Memorial Hospital Research Institute · PLHoly Cross University · PLPolish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chemokines play a crucial role in tumor growth and progression according to proangiogenic and immunosuppressive action. The aim of this study was to investigate the serum levels of selected chemokines in patients with ovarian cancer or benign ovarian tumors to assess their role in tumorigenesis and their potential use in preoperative diagnosis of an adnexal mass. Material and methods: The study group consisted of 59 women with ovarian cancer: 17 epithelial ovarian cancer (EOC) patients and 42 women with benign ovarian tumors. We measured in sera obtained preoperatively the level of CA125 and a panel of 5 chemokines - CX3CL1/fractalkine, CXCL1/GRO-α, CXCL12/SDF-1, CCL20/MIP-3α and IL-17F - using the chemiluminescence method with multiplexed bead based immunoassay. Results: CX3CL1 was significantly elevated in sera of advanced ovarian cancer patients compared to women with benign ovarian tumors. The significant elevation of CXCL1 was also observed (both early and advanced stages). A similar pattern was present with the standard ovarian cancer marker CA125. In our patients with endometriotic cysts CA125 levels were significantly higher than in women with other benign tumors, whereas all analyzed chemokines had similar serum titers in patients with endometriotic vs. other benign ovarian cysts. Conclusions: CX3CL1 and CXCL1 are elevated in sera of EOC patients, which indicates their role in cancer development. Moreover, they might be useful in preoperative differential diagnosis of ovarian tumors, especially as they were not elevated in cases of endometriosis.

Indexed as

CX3CL1CXCL1endometriosisovarian cancer

Identifiers

PMID35591828
PMCPMC9102528
OpenAlexW3151026885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.